Zocef

# Zocef ## Overview - **Classification**: Cephalosporin antibiotic (2nd generation) - **Mechanism**: Inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to bacterial cell lysis. ## Primary Indications 1. **Pharyngitis/Tonsillitis**: Streptococcal pharyngitis. 2. **Acute Bacterial Otitis Media**: Middle ear infections. 3. **Acute Bacterial Exacerbations of Chronic Bronchitis**: Respiratory tract infections. 4. **Community-Acquired Pneumonia**: Lung infections. 5. **Uncomplicated Skin & Skin Structure Infections**: Cellulitis, impetigo. 6. **Uncomplicated Urinary Tract Infections**: Cystitis. 7. **Uncomplicated Gonorrhea**: Neisseria gonorrhoeae infections. 8. **Early Lyme Disease**: Erythema migrans. ## Adult Dosing ### Standard Dosing **Pharyngitis/Tonsillitis, Uncomplicated UTI** - **Dose**: **250 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Duration**: 5-10 days **Acute Bacterial Otitis Media, Impetigo** - **Dose**: **250 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Duration**: 10 days (Otitis Media), 7-10 days (Impetigo) **Acute Bacterial Exacerbations of Chronic Bronchitis, Community-Acquired Pneumonia** - **Dose**: **500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Duration**: 10 days **Uncomplicated Skin & Skin Structure Infections** - **Dose**: **250-500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Duration**: 7-10 days **Uncomplicated Gonorrhea** - **Dose**: **1000 mg** - **Frequency**: Single dose - **Route**: Oral (PO) - **Special Considerations**: Administer with probenecid **1 g** PO for enhanced effect. **Early Lyme Disease** - **Dose**: **500 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Duration**: 20 days ### Dose Adjustments - **Renal Impairment**: - CrCl >30 mL/min: No adjustment. - CrCl 10-29 mL/min: Usual dose every **24 hours**. - CrCl <10 mL/min: Usual dose every **48 hours**. - Hemodialysis: Administer usual dose after dialysis session. - **Hepatic Impairment**: No specific dose adjustment necessary. - **Elderly Patients**: Adjust dose based on renal function if impaired. ## Pediatric Dosing ### Neonates (0-28 days) - **Oral cefuroxime axetil (Zocef)**: Generally **not recommended** due to limited data and potential for accumulation in immature renal systems. Consider alternative antibiotics or IV cefuroxime if clinically indicated. ### Infants (1-12 months) - **Pharyngitis/Tonsillitis, Uncomplicated UTI** - **Dose**: **125 mg** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Maximum**: **250 mg** BID - **Acute Bacterial Otitis Media** - **Dose**: **15 mg/kg/dose** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Maximum**: **250 mg** BID - **Special Notes**: Use oral suspension; calculate dose carefully based on weight. ### Children (1-12 years) - **Pharyngitis/Tonsillitis, Uncomplicated UTI, Impetigo** - **Dose**: **125 mg** or **10 mg/kg/dose** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Maximum**: **250 mg** BID - **Acute Bacterial Otitis Media, More Severe Infections (e.g., Bronchitis, Pneumonia)** - **Dose**: **15 mg/kg/dose** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Maximum**: **500 mg** BID (equivalent to adult dose) - **Early Lyme Disease** - **Dose**: **15 mg/kg/dose** - **Frequency**: Twice daily (BID) - **Route**: Oral (PO) - **Maximum**: **250 mg** BID - **Duration**: 20 days ### Adolescents (13-18 years) - **Dose**: Generally follows **adult dosing guidelines**. - **Maximum**: **500 mg** BID (up to **1000 mg** for single dose gonorrhea). - **Special Notes**: Consider weight-based dosing for lower weight adolescents, but often transitions to adult fixed doses. ## Safety Information ### Contraindications - **Absolute**: Hypersensitivity to cefuroxime or other cephalosporin antibiotics. - **Absolute**: History of severe immediate hypersensitivity reaction (e.g., anaphylaxis) to any penicillin. - **Relative**: History of other types of penicillin hypersensitivity (e.g., rash) due to potential for cross-reactivity. ### Common Adverse Effects - **Very Common (>10%)**: Diarrhea. - **Common (1-10%)**: Nausea, vomiting, abdominal pain, headache, dizziness, candidiasis (oral/vaginal). - **Serious but Rare**: *Clostridioides difficile*-associated diarrhea (CDAD), severe hypersensitivity reactions (anaphylaxis, Stevens-Johnson Syndrome, toxic epidermal necrolysis), hemolytic anemia, cholestatic jaundice. ### Key Drug Interactions - **Antacids/H2-blockers/PPIs**: May reduce bioavailability of cefuroxime axetil (Zocef) by altering gastric pH. - **Clinical significance**: Decreased absorption, potentially reduced efficacy. - **Management**: Administer Zocef with food to improve absorption, avoid concurrent use or separate administration by several hours if possible. - **Oral Contraceptives**: Theoretical reduction in efficacy due to alteration of gut flora. - **Clinical significance**: Risk of contraceptive failure. - **Management**: Counsel patients to use a reliable non-hormonal birth control method. - **Probenecid**: Decreases renal tubular secretion of cefuroxime. - **Clinical significance**: Increased and prolonged cefuroxime serum concentrations. - **Management**: May be used intentionally (e.g., for gonorrhea), otherwise monitor for enhanced antibiotic effects. - **Warfarin**: May enhance anticoagulant effect. - **Clinical significance**: Increased INR, bleeding risk. - **Management**: Monitor INR closely, especially when initiating or discontinuing Zocef. ## Monitoring & Follow-up - **Before Treatment**: Obtain detailed allergy history (especially to penicillins and cephalosporins). - **During Treatment**: Monitor for resolution of infection symptoms. Assess for signs of adverse effects (e.g., rash, severe diarrhea). - **Clinical Signs**: Watch for persistent diarrhea (rule out CDAD), new or worsening rash, signs of superinfection (e.g., oral thrush, vaginal yeast infection). ## Clinical Pearls - 💡 **Take with Food**: Always advise patients to take Zocef (cefuroxime axetil) with food to enhance absorption and minimize gastrointestinal upset. - 💡 **Suspension Taste**: The oral suspension has a distinctive, often disliked, taste. Counsel patients, especially parents, to ensure compliance. Shake suspension well before each use. - 💡 **Complete Course**: Emphasize completing the full prescribed course of therapy, even if symptoms improve, to prevent resistance and relapse. - 💡 **Superinfection**: Be aware of the risk of superinfection, especially candidiasis and CDAD, with prolonged use. > **⚠️ Important**: This information is for educational purposes only. Always consult current prescribing information, local guidelines, and clinical judgment before prescribing.